

## Sun Pharma gets 'buy' rating

Mumbai-based pharmaceutical major Sun Pharma is expected to post a strong revenue growth on the back of its product pipeline in the United States. While a meaningful contribution to this growth is being led by Doxil (J&J supplies to be restored only in 2014) and recently acquired URL Pharma, Sun Pharma's own pipeline is estimated to witness revenue CAGR of 40 per cent to \$600 million. The broking house assumes a flat sales growth for Taro as it expects incremental competition to impact the market share for key Taro products. If competition is delayed or loss in market share is bridged by contribution from new launches, Taro may post a positive surprise. The broking house feels the current valuations are reasonable in light of the core earnings' growth of 30 per cent over FY13-FY15. It hence maintains a buy rating. Broking House: Motilal Oswal  
Rating: Buy  
Closing price: ₹571.10